-
Cerebral amyloid angiopathy decades after red blood cell transfusions: a report of two cases from a prospective cohort Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-18 K. Kaushik, M. J. H. Wermer, E. S. van Etten
Patients who underwent red blood cell (RBC) transfusion from donors who later developed multiple spontaneous intracerebral hemorrhages (ICHs) have recently been identified to have increased risk of ICH themselves. This increased risk of ICH was hypothesized to be related to iatrogenic cerebral amyloid angiopathy (iCAA) transmission. Two cases are presented who had RBC transfusion as an infant and presented
-
Re‐evaluating patient communication and care in angiographically negative subarachnoid hemorrhage: Balancing realism and optimism Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-16 Sara Khosdelazad, Jacoba M. Spikman, Sofie Solvang, Marieke J. H. Wermer, Niall Pender, Lieke S. Jorna, Sandra E. Rakers, Anouk van der Hoorn, Mohsen Javadpour, Rob J. M. Groen, Anne M. Buunk
Angiographically negative subarachnoid hemorrhage (anSAH) has traditionally been considered a benign condition, mainly because of favorable outcomes in the acute stage in comparison to the often negative acute outcomes of aneurysmal subarachnoid hemorrhage. However, a growing body of research in recent years shows that anSAH often leads to cognitive impairments, emotional distress, and difficulties
-
Inter-hospital transfer for thrombectomy: transfer time is brain Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-14 Pierre Seners, Maeva Khyheng, Julien Labreuche, Bertrand Lapergue, Fernando Pico
-
-
Frequency of ischaemic stroke and intracranial haemorrhage in patients with reversible cerebral vasoconstriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) – A systematic review Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-12 Jana Kaufmann, Philipp Buecke, Thomas Meinel, Morin Beyeler, Adrian Scutelnic, Johannes Kaesmacher, Adnan Mujanović, Thomas Dobrocky, Hakim Arsany, Nils Peters, Werner Z'Graggen, Simon Jung, David Seiffge
BackgroundPosterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) may cause ischaemic stroke and intracranial haemorrhage. The aim of our study was to assess the frequency of the afore‐mentioned outcomes.MethodsWe performed a PROSPERO‐registered (CRD42022355704) systematic review and meta‐analysis accessing PubMed until 7 November 2022. The inclusion
-
Distinct neural signatures of pulvinar in C9orf72 amyotrophic lateral sclerosis mutation carriers and noncarriers Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-12 Anna Nigri, Mario Stanziano, Davide Fedeli, Umberto Manera, Stefania Ferraro, Jean Paul Medina Carrion, Sara Palermo, Laura Lequio, Federica Denegri, Federica Agosta, Edoardo Gioele Spinelli, Massimo Filippi, Marina Grisoli, Maria Consuelo Valentini, Filippo De Mattei, Antonio Canosa, Andrea Calvo, Adriano Chiò, Maria Grazia Bruzzone, Cristina Moglia
Background and purposeThalamic alterations have been reported as a major feature in presymptomatic and symptomatic patients carrying the C9orf72 mutation across the frontotemporal dementia–amyotrophic lateral sclerosis (ALS) spectrum. Specifically, the pulvinar, a high‐order thalamic nucleus and timekeeper for large‐scale cortical networks, has been hypothesized to be involved in C9orf72‐related neurodegenerative
-
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD) Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-12 Philip Van Damme, Ammar Al‐Chalabi, Peter M. Andersen, Adriano Chiò, Philippe Couratier, Mamede De Carvalho, Orla Hardiman, Magdalena Kuźma‐Kozakiewicz, Albert Ludolph, Christopher J. McDermott, Jesus S. Mora, Susanne Petri, Katrin Probyn, Evy Reviers, François Salachas, Vincenzo Silani, Ole‐Bjørn Tysnes, Leonard H. van den Berg, Gemma Villanueva, Markus Weber
BackgroundThis update of the guideline on the management of amyotrophic lateral sclerosis (ALS) was commissioned by the European Academy of Neurology (EAN) and prepared in collaboration with the European Reference Network for Neuromuscular Diseases (ERN EURO‐NMD) and the support of the European Network for the Cure ALS (ENCALS) and the European Organization for Professionals and Patients with ALS (EUpALS)
-
Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-11 Georgios Mangioris, Thorvardur R. Halfdanarson, Vanda A. Lennon, Bryce K. Chang, Divyanshu Dubey, P. James B. Dyck, Eoin P. Flanagan, Andrew McKeon, John R. Mills, Sean J. Pittock, Anastasia Zekeridou
Background and purposeParaneoplastic neurological autoimmunity is well described with small‐cell lung cancer, but information is limited for other neuroendocrine neoplasms (NENs).MethodsAdult patients with histopathologically confirmed non‐pulmonary NENs, neurological autoimmunity within 5 years of NEN diagnosis, and neural antibody testing performed at the Mayo Clinic Neuroimmunology Laboratory (January
-
Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-11 Maria Janina Wendebourg, Matthias Weigel, Claudia Weidensteiner, Laura Sander, Eva Kesenheimer, Nicole Naumann, Tanja Haas, Philipp Madoerin, Nathalie Braun, Christoph Neuwirth, Markus Weber, Kathleen Jahn, Ludwig Kappos, Cristina Granziera, Kathi Schweikert, Michael Sinnreich, Oliver Bieri, Regina Schlaeger
Background and purposeIn amyotrophic lateral sclerosis (ALS), there is an unmet need for more precise patient characterization through quantitative, ideally operator‐independent, assessments of disease extent and severity. Radially sampled averaged magnetization inversion recovery acquisitions (rAMIRA) magnetic resonance imaging enables gray matter (GM) and white matter (WM) area quantitation in the
-
Type 2 diabetes mellitus duration and subsequent risk of Alzheimer disease Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-07 Tomoyuki Kawada
I read a commentary article ‘Time-dependent impact of type 2 diabetes mellitus on incident prodromal Alzheimer disease’ [1] with great interest. Luo et al. investigated the association between type 2 diabetes mellitus (T2DM) and Alzheimer disease (AD), focusing on diabetes duration and comorbidities. The adjusted hazard ratio (HR) (95% confidence interval [CI]) of T2DM duration ≥5 years for AD was
-
Reply to the letter by Yin et al. ‘Reevaluating the impact of antihypertensive medication on intracranial aneurysm formation: a call for clarification and further study’ Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-06 Juhana Frösen, Sari Räisänen, Antti Lindgren
We thank Dr Yin and colleagues for their interest in our work. In their letter, Yin and colleagues wish to underline the need to study whether antihypertensive medication can reduce the rate of formation of intracranial aneurysms. We agree that this is an important topic with high clinical relevance, and hence we have undertaken the effort of making our study [1]. In our study, we compared the use
-
Association between sun exposure habits and disease progression in multiple sclerosis Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-05 Jing Wu, Tomas Olsson, Lars Alfredsson, Anna Karin Hedström
Background and purposeHigher latitude has been associated with increased occurrence of multiple sclerosis (MS) and with more severe disease. The aim was to study the impact of sun exposure habits on MS disease progression and health‐related quality of life.MethodsPatients from a population‐based case–control study were categorized based on sun exposure habits at diagnosis and were followed up to 15
-
Lessons from the past to understand the future Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-05 Didier Leys, Claudia Sommer, Barbara Borroni, Andrew Chan, Mark Edwards, Alessandro Tessitore, Kristl Vonck
-
Challenges to epilepsy management in Rwandan women living with epilepsy Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-02 Dirk E. Teuwen, Arlène Ndayisenga, Ieme Garrez, Fidèle Sebera, Sylvestre Mutungirehe, Josiane Umwiringirwa, Mustapha Ndiaye, Georgette Umuhoza, Paul A. J. M. Boon, Peter Dedeken
Background and purposeIn Rwanda, epilepsy prevalence ranges between 29‰ and 49‰. Many women living with epilepsy (WwE) are of childbearing age. Epilepsy characteristics and management, contraception, pregnancy, puerperium and stigma in WwE presenting at the neurology clinic of Ndera, Rwanda, were investigated.MethodsThis prospective cross‐sectional study investigated demographics, epilepsy characteristics
-
Multidisciplinary management and care in rare neuromuscular disorders: A call for action Eur. J. Neurol. (IF 5.1) Pub Date : 2024-03-01 Kristin Ørstavik, Andreas Dybesland Rosenberger, Hanne Ludt Fossmo, Marianne Nordstrøm, Marianne de Visser
Rare neuromuscular disorders (NMDs) comprise a large spectrum of diseases that may be present at all ages, at birth or they may develop during early infancy or childhood, in adulthood, or late in life. The European definition of a rare disease is one that affects <1 in 2000 people. Many are hereditary, such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), myotonic dystrophy, and
-
Reevaluating the impact of antihypertensive medication on intracranial aneurysm formation: a call for clarification and further study Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-29 Zihan Yin, Anjie Wang, Jizong Zhao
Recently, we read with great interest the article ‘Use of antihypertensive medication and formation of de novo intracranial aneurysms’ by Räisänen et al. [1]. The study found that antihypertensive drugs were not associated with a reduction in de novo saccular intracranial aneurysm (sIA) formation, with the hazard ratio (HR) estimated at 1.60 (95% confidence interval [CI] 0.84–3.06) in the multivariate
-
Clinical variables contributing to the identification of biologically defined subgroups within cognitively unimpaired and mild cognitive impairment individuals Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-27 Sofia Marcolini, Jaime D. Mondragón, Zeus T. Dominguez-Vega, Peter P. De Deyn, Natasha M. Maurits
-
Value of intravenous alteplase before thrombectomy among patients with tandem lesions and emergent carotid artery stenting: A subgroup analysis of the SWIFT DIRECT trial Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-26 Adnan Mujanovic, Tomas Dobrocky, Waltraud Pfeilschifter, Luca Remonda, Jildaz Caroff, Daniel Behme, David J. Seiffge, Carlo W. Cereda, Georg Kägi, Joe Leyon, Eike I. Piechowiak, Vincent Costalat, Judith Wagner, Emmanuel Chabert, Thomas R. Meinel, Olav Jansen, Angelika Alonso, Christian Loehr, David S. Liebeskind, Jan Gralla, Urs Fischer, Johannes Kaesmacher
The value of intravenous thrombolysis (IVT) in eligible tandem lesion patients undergoing endovascular treatment (EVT) is unknown. We investigated treatment effect heterogeneity of EVT + IVT versus EVT-only in tandem lesion patients. Additional analyses were performed for patients undergoing emergent internal carotid artery (ICA) stenting.
-
Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-28 Dimos‐Dimtirios D. Mitsikostas, Edoardo Caronna, Marina De Tommaso, Christina I. Deligianni, Esme Ekizoglu, Hayrunnisa Bolay, Carl H. Göbel, Espen Saxhaug Kristoffersen, Christian Lampl, Elena Moro, Patricia Pozo‐Rosich, Johann Sellner, Gisela Terwindt, Pablo Irimia Sieira
Background and purposeThe aim was to provide insights to the characteristics of headache in the context of COVID‐19 on behalf of the Headache Scientific Panel and the Neuro‐COVID‐19 Task Force of the European Academy of Neurology (EAN) and the European Headache Federation (EHF).MethodsFollowing the Delphi method the Task Force identified six relevant questions and then conducted a systematic literature
-
Etiological distribution of isolated oculomotor nerve palsy: analysis of 633 patients and literature review Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-27 Hyun‐Jae Kim, Hyo‐Jung Kim, Jeong‐Yoon Choi, Hee Kyung Yang, Jeong‐Min Hwang, Ji‐Soo Kim
Background and purposeThe etiological distribution of oculomotor nerve palsy has varied amongst the studies. This study aimed to define the clinical features and underlying etiologies of isolated oculomotor nerve palsy by recruiting patients from all departments in a referral‐based university hospital.MethodsThe medical records of 672 patients who had a confirmed diagnosis of isolated oculomotor nerve
-
Biomarkers of neurodegeneration in isolated and antidepressant‐related rapid eye movement sleep behavior disorder Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-27 Francesco Biscarini, Fabio Pizza, Stefano Vandi, Alex Incensi, Elena Antelmi, Vincenzo Donadio, Raffaele Ferri, Rocco Liguori, Giuseppe Plazzi
Background and purposeThis study compared the features of isolated rapid eye movement (REM) sleep behavior disorder (iRBD) and antidepressant‐related REM sleep behaviour disorder (RBD) with the aim of highlighting markers that might distinguish the two entities.MethodsThe observational cohort study included RBD patients with and without antidepressant use (antiD+ and antiD− patients, respectively)
-
Intermediate conduction velocity in two cases of Charcot−Marie−Tooth disease type 1A Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-27 Pedro José Tomaselli, Julian Blake, James M. Polke, Osvaldo José Moreira do Nascimento, Mary M. Reilly, Wilson Marques Júnior, Matilde Laurá
Background and purposeCharcot−Marie−Tooth disease type 1A (CMT1A) is the most prevalent hereditary neuropathy worldwide and classically has slow nerve conduction velocity (NCV), in most cases below 38 m/s. Two unrelated patients with motor NCVs in the upper limbs above 38 m/s are reported.MethodCase report.ResultsTwo genetically confirmed CMT1A patients are presented, from two unrelated families (one
-
Experiences from a cluster‐randomized trial (ParaNASPP) exploring triage and diagnostic accuracy in paramedic‐suspected stroke: a qualitative interview study Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-26 Mona Guterud, Camilla Hardeland, Helge Fagerheim Bugge, Else Charlotte Sandset, Edel Jannecke Svendsen, Maren Ranhoff Hov
Background and purposeTimely prehospital stroke recognition was explored in the Paramedic Norwegian Acute Stroke Prehospital Project (ParaNASPP) by implementation of stroke education for paramedics and use of the National Institutes of Health Stroke Scale (NIHSS) through a mobile application. The study tested triage and facilitated communication between paramedics and stroke physicians. To complement
-
Frequency and outcomes of gastrostomy insertion in a longitudinal cohort study of atypical parkinsonism Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-26 Christopher Kobylecki, Viorica Chelban, Yee Yen Goh, Emilia Michou, Riona Fumi, Marte Theilmann Jensen, Rahema Mohammad, Alyssa Costantini, Nirosen Vijiaratnam, Samantha Pavey, Nicola Pavese, P. Nigel Leigh, James B. Rowe, Michele T. Hu, Alistair Church, Huw R. Morris, Henry Houlden
BackgroundMultiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) show a high prevalence and rapid progression of dysphagia, which is associated with reduced survival. Despite this, the evidence base for gastrostomy is poor, and the optimal frequency and outcomes of this intervention are not known. We aimed to characterise the prevalence and outcomes of gastrostomy
-
Unusual combinations of neurodegenerative pathologies with chronic traumatic encephalopathy (CTE) complicates clinical prediction of CTE Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-26 Foad Taghdiri, Mozhgan Khodadadi, Nusrat Sadia, Asma Mushtaque, Olivia F. T. Scott, Veronica Hirsch‐Reinhagen, Charles Tator, Richard Wennberg, Gabor G. Kovacs, M. Carmela Tartaglia
Background and purposeChronic traumatic encephalopathy (CTE) has gained widespread attention due to its association with multiple concussions and contact sports. However, CTE remains a postmortem diagnosis, and the link between clinical symptoms and CTE pathology is poorly understood. This study aimed to investigate the presence of copathologies and their impact on symptoms in former contact sports
-
Clinical observations in acute neurology: A historical explanation of the present Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-26 Eelco F. M. Wijdicks
BackgroundThe history of the development of acute neurologic disease as a biologic mechanism is of interest. Equally important is how it translated to the bedside and how the clinical examination differentiated itself.MethodsThis paper reviews primary sources pertaining to acute neurologic conditions described mostly in the 19th and 20th century. A review of monographs, treatises, textbooks, and peer‐reviewed
-
Functional neurological disorder, factitious disorder, and the missing health care workers Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-24 Richard A. Kanaan
Dear Editor, Vanini et al. (2024) [1] are careful to explain that their findings of increased health care employment in a functional neurological disorder (FND) cohort should not be taken to imply feigning, and with good reason. In addition to the risk of stigmatizing the FND population, conflating two disorders with such different hypothetical mechanisms, and such different prevalence, would be absurd
-
Testing the specificity of phenomenological criteria for functional tic‐like behaviours in youth with Tourette syndrome Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-24 Christelle Nilles, Davide Martino, Tamara Pringsheim
Background and purposeThe aim was to test the specificity of phenomenological criteria for functional tic‐like behaviours (FTLBs). The European Society for the Study of Tourette Syndrome (ESSTS) criteria for the diagnosis of FTLBs include three major criteria: age at symptom onset ≥12 years, rapid evolution of symptoms and specific phenomenology.MethodsChildren and adolescents with primary tic disorders
-
Reply to “Serum neurofilament light chain and small fiber neuropathy: Every cloud has a silver lining” by D. Plantone and G. Primiano Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-20 Panoraia Baka, Frank Birklein, Stefan Bittner, Claudia Sommer
We wish to thank Drs Plantone and Primiano for their insightful comments on our study. We fully agree that having a marker, that is specific for peripheral nerve damage would be appealing. However, we do not think that the claim for neurofilament light chain (NfL) being a marker of just central nervous system damage is justified. Numerous studies on peripheral nerve disease, most notably Guillain–Barré
-
Early history of the European Journal of Neurology. A mirror of the evolution of Europe after 1989 Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-21 François Boller, Anne Petrov, Per Soelberg Sørensen
This paper retraces the early history of the European Journal of Neurology (EJN), as it is about to enter its 30th year. It describes how our discipline organized itself during the latter part of the 20th century in Europe. In some ways, the creation and the evolution of the journal parallel the process of unification of Europe in its current form in the late 1980s and early 1990s. It started as a
-
Assessment of diagnostic criteria for multifocal motor neuropathy in patients included in the Italian database Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-20 Pietro Emiliano Doneddu, Luca Gentile, Dario Cocito, Raffaella Fazio, Marco Luigetti, Chiara Briani, Massimiliano Filosto, Gabriele Siciliano, Luana Benedetti, Giovanni Antonini, Sabrina Matà, Girolama Alessandra Marfia, Maurizio Inghilleri, Fiore Manganelli, Giuseppe Cosentino, Filippo Brighina, Marinella Carpo, Francesca Carta, Anna Mazzeo, Erdita Peci, Camilla Strano, Angela Romano, Marta Campagnolo
Background and purposeThis study aimed to assess the diagnostic criteria, ancillary investigations and treatment response using real‐life data in multifocal motor neuropathy (MMN) patients.MethodsClinical and laboratory data were collected from 110 patients enrolled in the Italian MMN database through a structured questionnaire. Twenty‐six patients were excluded due to the unavailability of nerve conduction
-
Taking the pulse of brain death: A meta‐analysis of the natural history of brain death with somatic support Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-20 Ivancarmine Gambardella, Francesco Nappi, Berhane Worku, Robert F. Tranbaugh, Aminat M. Ibrahim, Sandhya K. Balaram, James L. Bernat
-
Cognitive domains affected post‐COVID‐19; a systematic review and meta‐analysis Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-20 Jack B. Fanshawe, Brendan F. Sargent, James B. Badenoch, Aman Saini, Cameron J. Watson, Aleksandra Pokrovskaya, Daruj Aniwattanapong, Isabella Conti, Charles Nye, Ella Burchill, Zain U. Hussain, Khanafi Said, Elinda Kuhoga, Kukatharmini Tharmaratnam, Sophie Pendered, Bernard Mbwele, Maxime Taquet, Greta K. Wood, Jonathan P. Rogers, Adam Hampshire, Alan Carson, Anthony S. David, Benedict D. Michael
Background and purposeThis review aims to characterize the pattern of post‐COVID‐19 cognitive impairment, allowing better prediction of impact on daily function to inform clinical management and rehabilitation.MethodsA systematic review and meta‐analysis of neurocognitive sequelae following COVID‐19 was conducted, following PRISMA‐S guidelines. Studies were included if they reported domain‐specific
-
Prevalence and clinical profiles of anti‐myelin‐associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-20 Yuya Aotsuka, Sonoko Misawa, Tomoki Suichi, Kazumoto Shibuya, Keigo Nakamura, Hiroki Kano, Ryo Otani, Marie Morooka, Moeko Ogushi, Kengo Nagashima, Yasunori Sato, Nagato Kuriyama, Satoshi Kuwabara
Background and purposeThe aim of this study was to determine the prevalence of anti‐myelin‐associated glycoprotein (MAG) neuropathy and the current status of such patients in Japan.MethodsWe conducted a nationwide survey in 2021 using established epidemiological methods. Questionnaires were sent to all neurology and pediatric neurology departments throughout Japan to identify patients with anti‐MAG
-
Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-20 Aglina Lika, Eleni‐Rosalina Andrinopoulou, Nadine A. M. E. van der Beek, Dimitris Rizopoulos, Ans T. van der Ploeg, Michelle E. Kruijshaar
Background and purposePompe disease is a rare, inheritable, progressive metabolic myopathy. This study aimed to estimate the minimal clinically important difference (MCID) for an improvement in forced vital capacity in the upright seated position (FVCup) and the 6‐min walk test (6MWT) after a year of treatment with enzyme replacement therapy.MethodsData were obtained from two prospective follow‐up
-
Rituximab treatment in pediatric‐onset multiple sclerosis Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-20 Markus Breu, Fredrik Sandesjö, Ruxandra‐Iulia Milos, Jan Svoboda, Jonatan Salzer, Lisa Schneider, Julian Benedikt Reichelt, Annikki Bertolini, Astrid Blaschek, Katharina Fink, Romana Höftberger, Jan Lycke, Kevin Rostásy, Rainer Seidl, Sandy Siegert, Ronny Wickström, Barbara Kornek
Background and purposeRituximab (RTX) is frequently used off‐label in multiple sclerosis. However, studies on the risk–benefit profile of RTX in pediatric‐onset multiple sclerosis are scarce.MethodsIn this multicenter retrospective cohort study, patients with pediatric‐onset multiple sclerosis from Sweden, Austria and Germany, who received RTX treatment were identified by chart review. Annualized relapse
-
Incidence rate and prevalence of pediatric‐onset multiple sclerosis in Sweden: A population‐based register study Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-19 Fredrik Sandesjö, Helen Tremlett, Katharina Fink, Ruth Ann Marrie, Feng Zhu, Ronny Wickström, Kyla A. McKay
Background and purposePediatric‐onset multiple sclerosis (PoMS) is associated with high health care use. To plan resource allocation for this patient group, knowledge of the incidence rate and prevalence is important. However, such studies are scarce, few are population‐based, and the methodology varies widely. We aimed to address this knowledge gap by performing a nationwide study of the incidence
-
A study on the role of serum uric acid in differentiating acute inflammatory demyelinating polyneuropathy from acute-onset chronic inflammatory demyelinating polyneuropathy Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-14 Weiyun Zhang, Wen Tao, Jun Wang, Ping Nie, Lihui Duan, Lanyun Yan
Clinical symptoms and laboratory indices for acute inflammatory demyelinating polyneuropathy (AIDP), a variant of Guillain−Barré syndrome, and acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) were analyzed to identify factors that could contribute to early differential diagnosis.
-
Long-term headache after spontaneous intracerebral haemorrhage Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-13 Ugur Gurol, Giuseppe Scopelliti, Charlotte Cordonnier, Laurent Puy
Though headache is commonly observed after stroke and may affect survivors' quality of life, it has rarely been studied after spontaneous intracerebral haemorrhage (ICH). In a cohort of ICH survivors, we assessed the long-term prevalence and determinants of headache.
-
Ocular motor and vestibular dysfunction in central nervous system lymphoma Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-12 Suk-Min Lee, Seo Young Choi, Jae-Hwan Choi, Eun Hye Oh, Dallah Yoo, Sun-Uk Lee, Hyo Jung Kim, Jeong-Yoon Choi, Ji-Soo Kim, Kwang-Dong Choi
Diagnosis of lymphoma involving the central nervous system (CNS) is challenging. This study aimed to explore the abnormal vestibular and ocular motor findings in CNS lymphoma.
-
Serum neurofilament light chain and small fiber neuropathy: Every cloud has a silver lining Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-12 Domenico Plantone, Guido Primiano
It was with great interest that we read the study by Baka et al. [1]. These authors explored the significance of serum neurofilament light chain (NfL) as a possible biomarker of small fiber neuropathy (SFN) by testing the sera of 30 patients and comparing the results to those from a cohort of 19 healthy individuals. No difference was found with regard to serum NfL levels in the two groups. Although
-
An assistive listening device improves hearing following aneurysmal subarachnoid haemorrhage Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-08 Ben Gaastra, Stuart Whyte, Bethan Hankin, Diederik Bulters, Ian Galea, Nicole Campbell
Hearing impairment is common following aneurysmal subarachnoid haemorrhage (aSAH). Previous studies have demonstrated that auditory processing disorder (APD) is the primary underlying pathology. Assistive listening devices (ALDs) can be used to manage APD but have not been explored in aSAH. The aim of this study was to assess the benefit of an ALD for patients reporting hearing difficulty after aSAH
-
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-07 Ana Beatriz Gago-Veiga, Noelia Lopez-Alcaide, Sonia Quintas, Iris Fernández Lázaro, Javier Casas-Limón, Carlos Calle, Germán Latorre, Nuria González-García, Jesús Porta-Etessam, Jaime Rodriguez-Vico, Alex Jaimes, Andrea Gómez García, David García-Azorín, Ángel Luis Guerrero-Peral, Álvaro Sierra, Alberto Lozano Ros, Antonio Sánchez-Soblechero, Javier Díaz-de-Teran, Javier A. Membrilla, Cristina Treviño
Anti-calcitonin gene-related peptide (CGRP) therapies are recent preventive therapies approved for both episodic and chronic migraine. One of the measures of effectiveness is the withdrawal of other preventive treatments. The objective of this study is to quantify the impact of anti-CGRP drugs in concomitant preventive treatment in patients with migraine.
-
The Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) score as a predictor for cognitive decline and potential surrogate outcome in the FINGER lifestyle randomized controlled trial Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-07 Anette Hall, Mariagnese Barbera, Jenni Lehtisalo, Riitta Antikainen, Hamidul Huque, Tiina Laatikainen, Tiia Ngandu, Hilkka Soininen, Ruth Stephen, Timo Strandberg, Miia Kivipelto, Kaarin J. Anstey, Alina Solomon
The complex aetiology of Alzheimer's disease suggests prevention potential. Risk scores have potential as risk stratification tools and surrogate outcomes in multimodal interventions targeting specific at-risk populations. The Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) was tested in relation to cognition and its suitability as a surrogate outcome in a multidomain lifestyle
-
Genetic insights into the relationship between immune cell characteristics and ischemic stroke: A bidirectional Mendelian randomization study Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-07 Xia Deng, Shuai Hou, Yanqiang Wang, Haiyan Yang, Chunping Wang
Ischemic stroke, a major contributor to global disability and mortality, is underpinned by intricate pathophysiological mechanisms, notably neuroinflammation and immune cell dynamics. Prior research has identified a nuanced and often paradoxical link between immune cell phenotypes and ischemic stroke susceptibility. The aim of this study was to elucidate the potential causal links between the median
-
The epidemiology and societal costs of myasthenia gravis in Norway: A non-interventional study using national registry data Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-07 Ingrid Engebretsen, Nils Erik Gilhus, Ivar Sønbø Kristiansen, Erik Magnus Sæther, Ingrid Lindberg-Schager, Fredrik Arneberg, Christoffer Bugge
With the emergence of new treatment options for myasthenia gravis (MG), there is a need for information regarding epidemiology, healthcare utilization, and societal costs to support economic evaluation and identify eligible patients. We aimed to enhance the understanding of these factors using nationwide systematic registry data in Norway.
-
Corrigendum to “Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database” Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-07
Antonazzo IC, Rozza D, Conti S, et al. Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database. Eur J Neurol. 2024;31:e16064. doi:10.1111/ene.16064 The affiliations of the co-authors Paolo Angelo Cortesi and Lorenzo Giovanni Mantovani was published as: Paolo Angelo Cortesi1, Lorenzo Giovanni Mantovani1 1Research Centre on Public Health (CESP)
-
Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-06 Nils Erik Gilhus, Henning Andersen, Linda Kahr Andersen, Marion Boldingh, Sini Laakso, Margret Oddny Leopoldsdottir, Sidsel Madsen, Fredrik Piehl, Trine Haug Popperud, Anna Rostedt Punga, Liselotte Schirakow, John Vissing
-
Benefits of influenza vaccine on stroke beyond preventing infection: Paradigm change or sheer bias? Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-08 Mitchell S. V. Elkind, Francisco J. de Abajo
In 2006, the American Heart Association and American College of Cardiology jointly recommended annual vaccination against influenza for patients with coronary artery disease to prevent recurrent cardiovascular events [1]. Those recommendations were based on a single randomized clinical trial [2] and observational studies. Subsequent observational studies, trials, and meta-analyses—while not unanimous—have
-
Generative artificial intelligence in neurology: Opportunities and risks Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-08 Antonio Cerasa, Byron Crowe
In this issue of the journal, Fonseca et al. [1] present results of a creative analysis comparing performance between human neurologists and a generative artificial intelligence (AI) on neurology boards-style questions. The authors utilized OpenAI's AI model Generative Pre-Trained Transformer 3.5 (GPT 3.5) and challenged it with a set of 188 questions pooled from the American Academy of Neurology's
-
Response to letter on European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain–Barré syndrome Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-07 Pieter A. van Doorn, Peter Y. K. Van den Bergh, Robert D. M. Hadden
Dear Editor, We respond to the letter of Drs. Li and Lu regarding the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on diagnosis and treatment of Guillain–Barré syndrome (GBS) [1]. Their question is why the GBS Guideline Task Force (TF) made a strong recommendation against the administration of a second course of intravenous immunoglobulins (IVIg; second immunoglobulin
-
Possible benefit of second intravenous immunoglobulin course in Guillain−Barré syndrome patients with potentially poor prognosis Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-05 Hai-Feng Li, Zuneng Lu
In this comprehensive guideline [1], a strong recommendation was proposed against giving a second intravenous immunoglobulin (IVIg) course in Guillain−Barré syndrome (GBS) patients with a poor prognosis. This is exclusively based on the negative results and potential increase of thromboembolic events in the SID-GBS trial [2]. Howevere, we have three concerns about this study. The modified Erasmus GBS
-
Cold stimulation of the oral cavity redistributes blood towards the brain in healthy volunteers Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-02 Ole Hensel
The aim of this study was to analyze cold stimulation-induced changes in cerebral and cardiac hemodynamics.
-
Association between dysphagia and symptoms of depression and anxiety after ischemic stroke Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-02 Anel Karisik, Benjamin Dejakum, Kurt Moelgg, Silvia Komarek, Thomas Toell, Lukas Mayer-Suess, Raimund Pechlaner, Stefanie Kostner, Simon Sollereder, Sophia J. Kiechl, Sonja Rossi, Gudrun Schoenherr, Wilfried Lang, Stefan Kiechl, Michael Knoflach, Christian Boehme
Dysphagia is associated with poor outcome, higher mortality, reduced quality of life, and social isolation. We investigate the relationship between swallowing impairment and symptoms of anxiety and depression after ischemic stroke.
-
Movement disorders following mechanical thrombectomy resulting in ischemic lesions of the basal ganglia: An emerging clinical entity Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-01 Leonardo Rigon, Danilo Genovese, Carla Piano, Valerio Brunetti, Valeria Guglielmi, Angelo Tiziano Cimmino, Irene Scala, Salvatore Citro, Anna Rita Bentivoglio, Eleonora Rollo, Riccardo Di Iorio, Aldobrando Broccolini, Roberta Morosetti, Mauro Monforte, Giovanni Frisullo, Pietro Caliandro, Alessandro Pedicelli, Anselmo Caricato, Giovanna Masone, Paolo Calabresi, Giacomo Della Marca
Post-stroke movement disorders (PMDs) following ischemic lesions of the basal ganglia (BG) are a known entity, but data regarding their incidence are lacking. Ischemic strokes secondary to proximal middle cerebral artery (MCA) occlusion treated with thrombectomy represent a model of selective damage to the BG. The aim of this study was to assess the prevalence and features of movement disorders after
-
Sex differences in acute stroke metrics and outcome dependent on COVID status Eur. J. Neurol. (IF 5.1) Pub Date : 2024-01-30 Lukas Mayer-Suess, João Pedro Marto, Davide Strambo, George Ntaios, Thanh Nguyen, Stefan Kiechl, Raimund Pechlaner, Raul Nogueira, Patrik Michel, Michael Knoflach
Biological sex is known to have an impact on quality metrics of acute stroke. We aimed to determine whether COVID positivity accentuates this effect and constitutes worse outcome.
-
Cognitive outcomes in Susac syndrome: A 2-year neuropsychological follow-up study Eur. J. Neurol. (IF 5.1) Pub Date : 2024-02-02 Tineke Van Vrekhem, Marijke Miatton, Dimitri Hemelsoet, Liesbeth Van Hijfte, Cathérine Dekeyser, Julie De Zaeytijd, Veroniek Van Driessche, Helen Van Hoecke, Leen Maes, Guy Laureys
Susac syndrome (SuS) is a rare, autoimmune, neurological disease characterized by a clinical triad of branch retinal artery occlusion, sensorineural hearing loss and encephalopathy. Neuropsychological functioning in SuS is little researched and the prevalence, nature, and evolution over time of cognitive deficits in SuS remain unclear. This study aimed to better understand the long-term neuropsychological
-
Misfolded alpha-synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment Eur. J. Neurol. (IF 5.1) Pub Date : 2024-01-25 Richard Smith, Hanna Hovren, Robert Bowser, Nadine Bakkar, Ralph Garruto, Albert Ludolph, John Ravits, Lia Gaertner, Davan Murphy, Russ Lebovitz
Alpha-synuclein (α-Syn) oligomers and fibrils have been shown to augment the aggregation of TAR DNA-binding Protein 43 (TDP-43) monomers in vitro, supporting the idea that TDP-43 proteinopathies such as ALS may be modulated by the presence of toxic forms of α-Syn. Recently, parkinsonian features were reported in a study of European patients and Lewy bodies have been demonstrated pathologically in a
-
Combined depth and scalp electroencephalographic monitoring in acute brain injury: Yield and prognostic value Eur. J. Neurol. (IF 5.1) Pub Date : 2024-01-25 Fang Yuan, Charlotte Damien, Sophie Schuind, Michele Salvagno, Fabio Silvio Taccone, Benjamin Legros, Nicolas Gaspard
Depth electroencephalography (dEEG) is an emerging neuromonitoring technology in acute brain injury (ABI). We aimed to explore the concordances between electrophysiological activities on dEEG and on scalp EEG (scEEG) in ABI patients.
-
RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine Eur. J. Neurol. (IF 5.1) Pub Date : 2024-01-25 Celia Romero del Rincón, Alicia Gonzalez-Martinez, Sonia Quintas, David García-Azorín, Iris Fernández Lázaro, Angel Luis Guerrero-Peral, Yesica Gonzalez Osorio, Sonia Santos-Lasaosa, Carmen González Oria, Norberto Sánchez Rodríguez, Fernando Iglesias Díez, Ana Echavarría Íñiguez, Sendoa Gil Luque, Mariano Huerta-Villanueva, Sergio Campoy Díaz, Albert Muñoz-Vendrell, Alberto Lozano Ros, Antonio Sánchez-Soblechero
According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12–18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption.